Major drugmakers likely to benefit from heart failure gold rush by Kyle Blankenship Tuesday, January 21, 2020 An SGLT2 arms race is currently underway for heart failure patients, and not without reason: the market will likely continue to boom this decade.
Novo's Ozempic scores major win with heart-helping FDA approval by Kyle Blankenship Friday, January 17, 2020 Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.
AstraZeneca's Farxiga speeds toward pioneering CV approval by Kyle Blankenship Monday, January 6, 2020 With a nod in heart failure patients already secured, AstraZeneca's Farxiga has now landed a priority review in patients with or without diabetes.
Lilly, BI's Jardiance whiffs in CV trial chasing Farxiga by Kyle Blankenship Friday, December 13, 2019 Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.
AHA: Lilly, BI's Jardiance drops CV hospitalizations over rivals by Kyle Blankenship Sunday, November 17, 2019 In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.
AHA: AZ's Farxiga data show big benefit in non-diabetics by Kyle Blankenship Saturday, November 16, 2019 AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics look particularly strong.
Eli Lilly, Boehringer's SGLT2 med hits snag in Type 1 diabetes by Kyle Blankenship Thursday, November 14, 2019 Eli Lilly and Boehringer Ingelheim failed to persuade an FDA expert panel that their SGLT2 med, Jardiance, could be repurposed for Type 1 diabetes.
Novo's Rybelsus still no bargain compared with Jardiance: ICER by Arlene Weintraub Friday, November 1, 2019 ICER concluded that Novo Nordisk's diabetes pill Rybelsus will be less cost-effective than Jardiance as an add-on therapy in type 2 diabetes.
AZ's Farxiga nabs first FDA cardiovascular nod by Kyle Blankenship Monday, October 21, 2019 AstraZeneca’s Farxiga is chasing an OK to treat heart failure regardless of a diabetes diagnosis. But in the meantime, it's scored a smaller nod.
Jardiance tops GLP-1s in real-world heart failure study by Carly Helfand Thursday, September 19, 2019 New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.
